Derm-Biome’s topical compounds have positive results in preclinical trial.
Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company, today announced 2 of its topical treatments for atopic dermatitis (AD) had a great inhibitory effect in a well-established mouse model of the disease.1
“Atopic dermatitis is an intensely itchy inflammatory skin disease that causes physical and psychological suffering in millions of people worldwide,” said Youwen Zhou, MD, PhD, professor of dermatology at the University of British Columbia, and directory of skin research program, Vancouver Coastal Health Research Institute, Canada. “The currently available therapies, including the most recent FDA approved drug, crisaborole, are unsatisfactory due to limitations in effectiveness or tolerability. Therefore, it is exciting to discover that several of Derm-Biome’s newly developed compounds far outperformed crisaborole in blocking the development of skin inflammation in a mouse model of atopic dermatitis. If confirmed in further experimental testing, these compounds hold strong potential to become the next generation of therapies for the treatment of atopic dermatitis.”
The Derm-Biome’s compounds were submitted for a US patent application titled COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY SKIN CONDITIONS that was filed on June 14, 2021, according to the release.
CEO of Derm-Biome, Gordon Eberwin, Vancouver, Canada, said the company was excited over the results for the trial as they had decided to develop a new generation of novel derivatives to create more effective treatments. He stated that the company believes they have a commercially viable drug candidate.
“We are absolutely thrilled with the recent findings that our compounds are highly efficacious in a very well-established mouse model of atopic dermatitis,” said CSO of Bio-Derm, Poul Sorensen, MD, PhD, Vancouver, Canada. “As a biomedical researcher with a long-standing interest in molecular therapeutics, I can unequivocally say that these types of dramatic in vivo results are exceedingly rare.”
A Clinical Trial Application (CTA) is expected to be submitted to Health Canada by the first quarter of 2022.
1. Derm-Biome Pharmaceuticals, Inc. reports positive results from a preclinical study in atopic dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole. BioSpace. Press release. Published September 16, 2021. Accessed September 16, 2021. https://www.biospace.com/article/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-drug-crisaborole/